Literature DB >> 25114401

Ocular adnexal lymphomas: report of 2 cases of mantle cell lymphomas and short review of literature.

Kamal Kant Sahu1, Preithy Uthamalingam2, Santhosh Sampath3, Jitender Jinagal4, Ashim Das2, Gaurav Prakash1, Pankaj Malhotra1, Subhash Chander Varma5.   

Abstract

Mantle cell lymphoma in ocular region is a rare phenomenon which can be either primary or secondary. Most of these cases are usually diagnosed after excisional biopsy of the involved area with first visit being in the Ophthalmology OPD. We share our experience of two such cases being referred from Ophthalmology OPD. 1st case is about a 52-year-old man who came for complaints of redness of left eye with excessive lacrimation. Examination revealed congestion of left temporal bulbar conjunctiva and a small pinkish outgrowth 2 × 2 cm adherent to temporal bulbar conjunctiva. 2nd case is a 55-year-old gentlemen who presented with complaints for 8 months duration of swelling left eyelid. Excisional biopsy and histopathological examination in both the cases were done to confirm the diagnosis. CECT head and neck were done at baseline and during follow up. These cases are being presented due to the rarity and dramatic response to chemotherapy.

Entities:  

Keywords:  Cyclin D1; Mantle cell lymphomas; Ocular adnexal lymphomas

Year:  2014        PMID: 25114401      PMCID: PMC4115091          DOI: 10.1007/s12288-014-0389-x

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  18 in total

1.  Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.

Authors:  Andrés J M Ferreri; Silvia Govi; Annalisa Colucci; Roberto Crocchiolo; Giulio Modorati
Journal:  Ophthalmology       Date:  2010-08-14       Impact factor: 12.079

2.  Ocular adnexal lymphoid proliferations: clinical, histologic, flow cytometric, and molecular analysis of forty-three cases.

Authors:  Nariman Sharara; Jeannine T Holden; Ted H Wojno; Andrew S Feinberg; Hans E Grossniklaus
Journal:  Ophthalmology       Date:  2003-06       Impact factor: 12.079

Review 3.  [Management of lymphoid hyperplasia of the ocular adnexa].

Authors:  A Lanuza García; A L López Ramos; J C Pinto Bonilla; C Rodríguez Pereira; V Cortés Vizcaíno
Journal:  Arch Soc Esp Oftalmol       Date:  2005-06

4.  Histology according to the Revised European-American Lymphoma Classification significantly predicts the prognosis of ocular adnexal lymphoma.

Authors:  M Nakata; Y Matsuno; N Katsumata; T Takenaka; Y Kobayashi; M Narabayashi; Y Kagami; H Ikeda; A Kaneko; K Tobinai
Journal:  Leuk Lymphoma       Date:  1999-02

5.  Mantle cell lymphoma in the ocular adnexal region.

Authors:  Audrey Looi; Randy D Gascoyne; Mukesh Chhanabhai; Joseph M Connors; Jack Rootman; Valerie A White
Journal:  Ophthalmology       Date:  2005-01       Impact factor: 12.079

6.  Mantle cell lymphoma in the orbital and adnexal region.

Authors:  P Rasmussen; L D Sjö; J U Prause; E Ralfkiaer; S Heegaard
Journal:  Br J Ophthalmol       Date:  2009-05-07       Impact factor: 4.638

7.  Outcome and prognostic factors in ocular adnexal lymphoma.

Authors:  Marin Nola; Adrian Lukenda; Magdolna Bollmann; Miro Kalauz; Marko Petrovecki; Reinhard Bollmann
Journal:  Croat Med J       Date:  2004-06       Impact factor: 1.351

8.  Survey of 1264 patients with orbital tumors and simulating lesions: The 2002 Montgomery Lecture, part 1.

Authors:  Jerry A Shields; Carol L Shields; Richard Scartozzi
Journal:  Ophthalmology       Date:  2004-05       Impact factor: 12.079

9.  Lymphoid infiltrates of the orbit and conjunctiva. A morphologic and immunophenotypic study of 99 cases.

Authors:  L J Medeiros; N L Harris
Journal:  Am J Surg Pathol       Date:  1989-06       Impact factor: 6.394

10.  Conjunctival mass as an initial presentation of mantle cell lymphoma: a case report.

Authors:  Mahsa Khanlari; Babak Bagheri; Reza Vojdani; Mohammad Mohammadianpanah; Shahram Paydar; Yahya Daneshbod
Journal:  BMC Res Notes       Date:  2012-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.